Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association ( HFA ) of the European Society of Cardiology ( ESC ) - Université Paris Cité Accéder directement au contenu
Article Dans Une Revue European Journal of Heart Failure Année : 2020

Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association ( HFA ) of the European Society of Cardiology ( ESC )

1 UMCG - University Medical Center Groningen [Groningen]
2 CIC 1418 - CIC - HEGP
3 PARCC (UMR_S 970/ U970) - Paris-Centre de Recherche Cardiovasculaire
4 DMU CARTE - CArdiovasculaire Rénal Transplantation nEurovasculaire [Paris]
5 HEGP - Hôpital Européen Georges Pompidou [APHP]
6 University of Naples Federico II = Università degli studi di Napoli Federico II
7 UniGe - Università degli studi di Genova = University of Genoa
8 IRCCS Ospedale Policlinico San Martino [Genoa, Italy]
9 Charité - UniversitätsMedizin = Charité - University Hospital [Berlin]
10 MHH - Medizinische Hochschule Hannover = Hannover Medical School
11 University Hospital of Würzburg
12 San Raffaele Pisana Scientific Institute for Resaearch
13 San Raffaele Institute Pisana
14 Vilnius University [Vilnius]
15 UMPCD - University of Medicine and Pharmacy “Carol Davila” Bucharest
16 Innate Pharma
17 UKE - Universitaetsklinikum Hamburg-Eppendorf = University Medical Center Hamburg-Eppendorf [Hamburg]
18 DZHK - German Center for Cardiovascular Research
19 UCY - University of Cyprus [Nicosia]
20 NKUA - National and Kapodistrian University of Athens
21 Hospital Universitari Germans Trias I Pujol [Badalona]
22 UAB - Universitat Autònoma de Barcelona = Autonomous University of Barcelona = Universidad Autónoma de Barcelona
23 ISC - Instituto de Salud Carlos III [Madrid]
24 Heidelberg University Hospital [Heidelberg]
25 Wrocław Medical University
26 Albert Einstein College of Medicine [New York]
27 University of Minnesota Medical School
28 Royal Marsden NHS Foundation Trust
29 Universität Heidelberg [Heidelberg] = Heidelberg University
30 WUSTL - Washington University in Saint Louis
31 Vanderbilt University Medical Center [Nashville]
32 CAU - Christian-Albrechts-Universität zu Kiel = Christian-Albrechts University of Kiel = Université Christian-Albrechts de Kiel
33 UNIGE - Université de Genève = University of Geneva
34 UNIPR - Università degli studi di Parma = University of Parma
35 University Hospital Hradec Kralove
36 Medical University of Graz
37 University hospital of Zurich [Zurich]
38 MMCRI - Maine Medical Center Research Institute
39 University of Belgrade [Belgrade]
40 UNIBE - Universität Bern / University of Bern
41 Universiteit Utrecht / Utrecht University [Utrecht]
42 Georg-August-University = Georg-August-Universität Göttingen
43 Maastricht University [Maastricht]
44 KU Leuven - Catholic University of Leuven = Katholieke Universiteit Leuven
45 Imperial College London
Pierre Dodion
  • Fonction : Auteur
Piotr Ponikowski

Résumé

The co-occurrence of cancer and heart failure (HF) represents a significant clinical drawback as each disease interferes with the treatment of the other. In addition to shared risk factors, a growing body of experimental and clinical evidence reveals numerous commonalities in the biology underlying both pathologies. Inflammation emerges as a common hallmark for both diseases as it contributes to the initiation and progression of both HF and cancer. Under stress, malignant and cardiac cells change their metabolic preferences to survive, which makes these metabolic derangements a great basis to develop intersection strategies and therapies to combat both diseases. Furthermore, genetic predisposition and clonal haematopoiesis are common drivers for both conditions and they hold great clinical relevance in the context of personalized medicine. Additionally, altered angiogenesis is a common hallmark for failing hearts and tumours and represents a promising substrate to target in both diseases. Cardiac cells and malignant cells interact with their surrounding environment called stroma. This interaction mediates the progression of the two pathologies and understanding the structure and function of each stromal component may pave the way for innovative therapeutic strategies and improved outcomes in patients. The interdisciplinary collaboration between cardiologists and oncologists is essential to establish unified guidelines. To this aim, pre-clinical models that mimic the human situation, where both pathologies coexist, are needed to understand all the aspects of the bidirectional relationship between cancer and HF. Finally, adequately powered clinical studies, including patients from all ages, and men and women, with proper adjudication of both cancer and cardiovascular endpoints, are essential to accurately study these two pathologies at the same time.

Dates et versions

hal-03676844 , version 1 (24-05-2022)

Identifiants

Citer

Rudolf Boer, Jean‐sébastien Hulot, Carlo Gabriele Tocchetti, Joseph Pierre Aboumsallem, Pietro Ameri, et al.. Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the Translational Research Committee of the Heart Failure Association ( HFA ) of the European Society of Cardiology ( ESC ). European Journal of Heart Failure, 2020, 22 (12), pp.2272-2289. ⟨10.1002/ejhf.2029⟩. ⟨hal-03676844⟩

Collections

UP-SANTE ANR FRM
11 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More